Special Programme on Human Reproduction: Difference between revisions

Revision as of 21:39, 22 December 2020

Revision as of 22:16, 25 December 2021

Line 1:

The '''Special Programme on Human Reproduction''' ('''HRP'''), also known as the '''Special Programme of Research, Development and Research Training in Human Reproduction''', was a [[World Health Organization]] (WHO) endeavor.<ref name="BenagianoMerialdi2011">Benagiano, G., & Merialdi, M. (2011). Carl Djerassi and the World Health Organisation special programme of research in human reproduction. Journal für Reproduktionsmedizin und Endokrinologie-Journal of Reproductive Medicine and Endocrinology, 8(1), 10-13. http://www.kup.at/kup/pdf/10163.pdf</ref><ref name="pmid8013216">{{cite journal | vauthors = Toppozada MK | title = Existing once-a-month combined injectable contraceptives | journal = Contraception | volume = 49 | issue = 4 | pages = 293–301 | date = April 1994 | pmid = 8013216 | doi = 10.1016/0010-7824(94)90029-9 }}</ref><ref name="pmid1829341">{{cite journal | vauthors = Koetsawang S | title = The injectable contraceptive: present and future trends | journal = Ann. N. Y. Acad. Sci. | volume = 626 | pages = 30–42 | date = 1991 | issue = 1 | pmid = 1829341 | doi = 10.1111/j.1749-6632.1991.tb37897.x | bibcode = 1991NYASA.626...30K | s2cid = 27008012 }}</ref>

It resulted in the following marketed [[combined injectable contraceptive]]s:<ref name="pmid8013216" /><ref name="pmid1829341" /><ref name="pmid1958567" /><ref name="pmid8013221">{{cite journal | vauthors = Koetsawang S | title = Once-a-month injectable contraceptives: efficacy and reasons for discontinuation | journal = Contraception | volume = 49 | issue = 4 | pages = 387–98 | date = April 1994 | pmid = 8013221 | doi = 10.1016/0010-7824(94)90034-5 }}</ref><ref name="pmid8013219">{{cite journal | vauthors = Garza-Flores J | title = Pharmacokinetics of once-a-month injectable contraceptives | journal = Contraception | volume = 49 | issue = 4 | pages = 347–59 | date = April 1994 | pmid = 8013219 | doi = 10.1016/0010-7824(94)90032-9 }}</ref><ref name="pmid8013222">{{cite journal | vauthors = Fraser IS | title = Vaginal bleeding patterns in women using once-a-month injectable contraceptives | journal = Contraception | volume = 49 | issue = 4 | pages = 399–420 | date = April 1994 | pmid = 8013222 | doi = 10.1016/0010-7824(94)90035-3 }}</ref><ref name="pmid10592855">{{cite journal | vauthors = Hassan EO, el-Nahal N, el-Hussinie M | title = Once-a-month injectable contraceptives, Cyclofem and Mesigyna, in Egypt. Efficacy, causes of discontinuation, and side effects | journal = Contraception | volume = 60 | issue = 2 | pages = 87–92 | date = August 1999 | pmid = 10592855 | doi = 10.1016/S0010-7824(99)00064-5 }}</ref><ref name="pmid8045129">{{cite journal | vauthors = Giwa-Osagie OF | title = Metabolic effects of once-a-month combined injectable contraceptives. The World Health Organization Task Force on Long-Acting Systemic Agents for Fertility Regulation, Geneva, Switzerland | journal = Contraception | volume = 49 | issue = 5 | pages = 421–33 | date = May 1994 | pmid = 8045129 | doi = 10.1016/0010-7824(94)90001-9 }}</ref>

Line 6:

* [[Estradiol valerate/norethisterone enanthate]] (EV/NETE; brand name Mesigyna; code name HRP-102)

And in the following never-marketed [[progestogen]] [[injection (medicine)|injectable]] [[hormonal contraceptive|contraceptive]]s:<ref name="BenagianoMerialdi2011" /><ref name="pmid1958567">{{cite journal | vauthors = Garza-Flores J, Hall PE, Perez-Palacios G | title = Long-acting hormonal contraceptives for women | journal = J. Steroid Biochem. Mol. Biol. | volume = 40 | issue = 4-64–6 | pages = 697–704 | date = 1991 | pmid = 1958567 | doi = 10.1016/0960-0760(91)90293-E | s2cid = 26021562 }}</ref>

* [[Levonorgestrel butanoate]] (LNG-B; code name HRP-002)